LNTH Lantheus Holdings Inc

Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time

Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time

BEDFORD, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) --   (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023, to discuss its financial and operating results for the third quarter of 2023.

To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

About Lantheus

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842



Melissa Downs

Senior Director, Corporate Communications

646-975-2533



EN
19/10/2023

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Reports First Quarter 2024 Financial Results

Lantheus Reports First Quarter 2024 Financial Results First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income per share of $1.47 in the first quarter 2023The Company increases full year 2024 net revenue and earnings guidance and provides guidance for the second quarter 2024 BEDFORD, Mass., May 02, 2024 (GLOBE NE...

2h / 23m 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host First Quarter 2024 Earnings Conference Call and Webca...

Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to discuss its financial and operating results for the first quarter of 2024. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be avai...

April 18, 2024 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at the Leerink Partners Global Biopharma Conferenc...

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024 BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12. To access a live webcast of the presentation, please visit the  section of the Company’s website at . A repla...

March 5, 2024 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Mic...

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow® disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA)...

March 4, 2024 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Offi...

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer BEDFORD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the promotion of Amanda Morgan to Chief Commercial Officer and her elevation to be a member of the company’s Executive Team, effective March 25, 2024. In her role, Ms. Morgan will continue to lead the Company’s commercial strategy and activities, incl...

February 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch